The Appropriate Use of Antibiotics in Surgery: A Review of Surgical Infections

Current Problems in Surgery

Volumn 44, Issue 10, 2007, Pages 635-675

  Hedrick, Traci L ^a   Smith, Philip W ^a   Gazoni, Leo M ^a   Sawyer, Robert G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CASPOFUNGIN; CEFAMANDOLE; CEFAZOLIN; CEFONICID; CEFOTETAN; CEFOXITIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; CYCLOSPORIN; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; GLYCOPEPTIDE; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NEOMYCIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ABDOMINAL PENETRATING TRAUMA; AGING; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL VIRULENCE; BREAST SURGERY; CANDIDIASIS; CATHETER INFECTION; CATHETER REMOVAL; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLORECTAL SURGERY; DIARRHEA; DISEASE TRANSMISSION; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG UTILIZATION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GRAFT REJECTION; HEART SURGERY; HERNIOPLASTY; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; INTRAVASCULAR CATHETER; LABORATORY TEST; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NECROTIZING FASCIITIS; PATIENT COMPLIANCE; PATIENT SELECTION; SINGLE DRUG DOSE; SKIN INFECTION; SKIN NECROSIS; SKIN STRUCTURE; SURGICAL DRAINAGE; SURGICAL INFECTION; TREATMENT DURATION; URINARY TRACT INFECTION;

ABDOMINAL INJURIES; ALGORITHMS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIURIA; CATHETERIZATION, CENTRAL VENOUS; CELLULITIS; CROSS INFECTION; DEBRIDEMENT; DIABETES MELLITUS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; IMMUNOCOMPROMISED HOST; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; SURGICAL WOUND INFECTION; URINARY CATHETERIZATION; URINARY TRACT INFECTIONS; WOUNDS, PENETRATING;

EID: 36049037973     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2007.06.006     Document Type: Article

References (178)

1. Mangram A.J., Horan T.C., Pearson M.L., Silver L.C., and Jarvis W.R. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Guideline for Prevention of Surgical Site Infection, 1999. Am J Infect Control 27 2 (1999) 97-132 quiz 3-4; discussion 96.
2. Guidelines for preventing health-care-associated pneumonia, 2003 recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. Respir Care 49 (2004) 926-939
3. Bailly P., Lallemand S., Thouverez M., and Talon D. Multicentre study on the appropriateness of surgical antibiotic prophylaxis. J Hosp Infect 49 (2001) 135-138
4. Bratzler D.W., and Houck P.M. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 38 (2004) 1706-1715
5. Barie P.S., and Eachempati S.R. Surgical site infections. Surg Clin North Am 85 (2005) 1115-1135
6. Stone H.H., Hooper C.A., Kolb L.D., Geheber C.E., and Dawkins E.J. Antibiotic prophylaxis in gastric, biliary and colonic surgery. Ann Surg 184 (1976) 443-452
7. Classen D.C., Evans R.S., Pestotnik S.L., Horn S.D., Menlove R.L., and Burke J.P. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 326 (1992) 281-286
8. Heineck I., Ferreira M.B.C., and Schenkel E.P. Prescribing practice for antibiotic prophylaxis for 3 commonly performed surgeries in a teaching hospital in Brazil. Am J Infect Control 27 (1999) 296-300
9. Vaisbrud V., Raveh D., Schlesinger Y., and Yinnon A.M. Surveillance of Antimicrobial Prophylaxis for Surgical Procedures. Infect Control Hosp Epidemiol 20 (1999) 610-613
10. Hosoglu S., Sunbul M., Erol S., et al. A National Survey of Surgical Antibiotic Prophylaxis in Turkey. Infect Control Hosp Epidemiol 24 (2003) 758-761
11. Bratzler D.W., and Houck P.M. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 189 (2005) 395-404
12. Platt R., Zaleznik D.F., Hopkins C.C., et al. Perioperative antibiotic prophylaxis for herniorrhaphy and breast surgery. N Engl J Med 322 (1990) 153-160
13. Platt R., Zucker J.R., Zaleznik D.F., et al. Prophylaxis against wound infection following herniorrhaphy or breast surgery. J Infect Dis 166 (1992) 556-560
14. Platt R., Zucker J.R., Zaleznik D.F., et al. Perioperative antibiotic prophylaxis and wound infection following breast surgery. J Antimicrob Chemother 31 suppl B (1993) 43-48
15. Cunningham M., Bunn F., and Handscomb K. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. Cochrane Database Syst Rev 2 (2006) CD005360
16. Lazorthes F., Chiotasso P., Massip P., Materre J.P., and Sarkissian M. Local antibiotic prophylaxis in inguinal hernia repair. Surg Gynecol Obstet 175 (1992) 569-570
17. Celdran A., Frieyro O., de la Pinta J.C., et al. The role of antibiotic prophylaxis on wound infection after mesh hernia repair under local anesthesia on an ambulatory basis. Hernia 8 (2004) 20-22
18. Yerdel M.A., Akin E.B., Dolalan S., et al. Effect of single-dose prophylactic ampicillin and sulbactam on wound infection after tension-free inguinal hernia repair with polypropylene mesh: the randomized, double-blind, prospective trial. Ann Surg 233 (2001) 26-33
19. Taylor E.W., Byrne D.J., Leaper D.J., Karran S.J., Browne M.K., and Mitchell K.J. Antibiotic prophylaxis and open groin hernia repair. World J Surg 21 (1997) 811-814 discussion 4-5.
20. Perez A.R., Roxas M.F., and Hilvano S.S. A randomized, double-blind, placebo-controlled trial to determine effectiveness of antibiotic prophylaxis for tension-free mesh herniorrhaphy. J Am Coll Surg 200 (2005) 393-397 discussion 7-8.
21. Aufenacker T.J., van Geldere D., van Mesdag T., et al. The role of antibiotic prophylaxis in prevention of wound infection after Lichtenstein open mesh repair of primary inguinal hernia: a multicenter double-blind randomized controlled trial. Ann Surg 240 (2004) 955-960 discussion 60-1.
22. Aufenacker T.J., Koelemay M.J., Gouma D.J., and Simons M.P. Systematic review and meta-analysis of the effectiveness of antibiotic prophylaxis in prevention of wound infection after mesh repair of abdominal wall hernia. Br J Surg 93 (2005) 5-10
23. Nichols R.L. Preventing surgical site infections: a surgeon's perspective. Emerg Infect Dis 7 (2001) 220-224
24. Milano C.A., Kesler K., Archibald N., Sexton D.J., and Jones R.H. Mediastinitis after coronary artery bypass graft surgery. Risk factors and long-term survival. Circulation 92 (1995) 2245-2251
25. Stamm A.M., Long M.N., and Belcher B. Higher overall nosocomial infection rate because of increased attack rate of methicillin-resistant Staphylococcus aureus. Am J Infect Control 21 (1993) 70-74
26. Edwards F.H., Engelman R.M., Houck P., Shahian D.M., and Bridges C.R. The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic prophylaxis in cardiac surgery, part I: duration. Ann Thorac Surg 81 (2006) 397-404
27. Harbarth S., Samore M.H., Lichtenberg D., and Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 101 (2000) 2916-2921
28. Manian F.A., Meyer P.L., Setzer J., and Senkel D. Surgical site infections associated with methicillin-resistant Staphylococcus aureus: do postoperative factors play a role?. Clin Infect Dis 36 (2003) 863-868
29. Caffarelli A.D., Holden J.P., Baron E.J., et al. Plasma cefazolin levels during cardiovascular surgery: effects of cardiopulmonary bypass and profound hypothermic circulatory arrest. J Thorac Cardiovasc Surg 131 (2006) 1338-1343
30. Zanetti G., and Platt R. Antibiotic prophylaxis for cardiac surgery: does the past predict the future?. Clin Infect Dis 38 (2004) 1364-1366
31. L'Ecuyer P.B., Murphy D., Little J.R., and Fraser V.J. The epidemiology of chest and leg wound infections following cardiothoracic surgery. Clin Infect Dis 22 (1996) 424-429
32. Finkelstein R., Rabino G., Mashiah T., et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 123 (2002) 326-332
33. Smith T.L., Pearson M.L., Wilcox K.R., et al., Glycopeptide-Intermediate Staphylococcus aureus Working Group. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 340 (1999) 493-501
34. Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. MMWR Morb Mortal Wkly Rep 42 30 (1993) 597-599
35. Bolon M.K., Morlote M., Weber S.G., Koplan B., Carmeli Y., and Wright S.B. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis 38 (2004) 1357-1363
36. Washington II J.A., Dearing W.H., Judd E.S., and Elveback L.R. Effect of preoperative antibiotic regimen on development of infection after intestinal surgery: prospective, randomized, double-blind study. Ann Surg 180 (1974) 567-572
37. Baum M.L., Anish D.S., Chalmers T.C., Sacks H.S., Smith Jr. H., and Fagerstrom R.M. A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. N Engl J Med 305 (1981) 795-799
38. Malangoni M.A., Song J., Herrington J., Choudhri S., and Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 244 (2006) 204-211
39. Lewis R.T. Oral versus systemic antibiotic prophylaxis in elective colon surgery: a randomized study and meta-analysis send a message from the 1990s. Can J Surg 45 (2002) 173-180
40. Espin-Basany E., Sanchez-Garcia J.L., Lopez-Cano M., et al. Prospective, randomised study on antibiotic prophylaxis in colorectal surgery. Is it really necessary to use oral antibiotics?. Int J Colorectal Dis 20 (2005) 542-546
41. Itani K.M., Wilson S.E., Awad S.S., Jensen E.H., Finn T.S., and Abramson M.A. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med 355 (2006) 2640-2651
42. Smith R.L., Bohl J.K., McElearney S.T., et al. Wound infection after elective colorectal resection. Ann Surg 239 (2004) 599-605 discussion 607.
43. Fullen W.D., Hunt J., and Altemeier W.A. Prophylactic antibiotics in penetrating wounds of the abdomen. J Trauma 12 (1972) 282-289
44. Thadepalli H., Gorbach S.L., Broido P.W., Norsen J., and Nyhus L. Abdominal trauma, anaerobes, and antibiotics. Surg Gynecol Obstet 137 (1973) 270-276
45. Luchette F.A., Borzotta A.P., Croce M.A., et al. Practice management guidelines for prophylactic antibiotic use in penetrating abdominal trauma: the EAST Practice Management Guidelines Work Group. J Trauma 48 (2000) 508-518
46. Bozorgzadeh A., Pizzi W.F., Barie P.S., et al. The duration of antibiotic administration in penetrating abdominal trauma. Am J Surg 177 (1999) 125-131
47. Fabian T.C., Croce M.A., Payne L.W., Minard G., Pritchard F.E., and Kudsk K.A. Duration of antibiotic therapy for penetrating abdominal trauma: a prospective trial. Surgery 112 (1992) 788-794 discussion 94-5.
48. Cornwell III E.E., Dougherty W.R., Berne T.V., et al. Duration of antibiotic prophylaxis in high-risk patients with penetrating abdominal trauma: a prospective randomized trial. J Gastrointest Surg 3 (1999) 648-653
49. Kirton O.C., O'Neill P.A., Kestner M., and Tortella B.J. Perioperative antibiotic use in high-risk penetrating hollow viscus injury: a prospective randomized, double-blind, placebo-control trial of 24 hours versus 5 days. J Trauma 49 (2000) 822-832
50. Hoth J.J., Franklin G.A., Stassen N.A., Girard S.M., Rodriguez R.J., and Rodriguez J.L. Prophylactic antibiotics adversely affect nosocomial pneumonia in trauma patients. J Trauma 55 (2003) 249-254
51. Hadjiminas D., Cheadle W.G., Spain D.A., et al. Antibiotic overkill of trauma victims?. Am J Surg 168 (1994) 288-290
52. Delgado Jr. G., Barletta J.F., Kanji S., Tyburski J.G., Wilson R.F., and Devlin J.W. Characteristics of prophylactic antibiotic strategies after penetrating abdominal trauma at a level I urban trauma center: a comparison with the East guidelines. J Trauma 53 (2002) 673-678
53. Mazuski J.E., Sawyer R.G., Nathens A.B., et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect (Larchmt) 3 (2002) 175-233
54. Bohnen J.M., Solomkin J.S., Dellinger E.P., Bjornson H.S., and Page C.P. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 127 (1992) 83-89 discussion 89.
55. Wong P.F., Gilliam A.D., Kumar S., Shenfine J., O'Dair G.N., and Leaper D.J. Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst Rev 2 (2005) CD004539
56. Solomkin J.S., Mazuski J.E., Baron E.J., et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 37 (2003) 997-1005
57. Krobot K., Yin D., Zhang Q., et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 23 (2004) 682-687
58. Cattan P., Yin D.D., Sarfati E., Lyu R., De Zelicourt M., and Fagnani F. Cost of care for inpatients with community-acquired intra-abdominal infections. Eur J Clin Microbiol Infect Dis 21 (2002) 787-793
59. Hopkins J.A., Lee J.C., and Wilson S.E. Susceptibility of intra-abdominal isolates at operation: a predictor of postoperative infection. Am Surg 59 (1993) 791-796
60. Dougherty S.H. Antimicrobial culture and susceptibility testing has little value for routine management of secondary bacterial peritonitis. Clin Infect Dis 25 suppl 2 (1997) S258-S261
61. Falagas M.E., Barefoot L., Griffith J., Ruthazar R., and Snydman D.R. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 15 (1996) 913-921
62. Mosdell D.M., Morris D.M., Voltura A., et al. Antibiotic treatment for surgical peritonitis. Ann Surg 214 (1991) 543-549
63. Gorecki P., Schein M., Rucinski J.C., and Wise L. Antibiotic administration in patients undergoing common surgical procedures in a community teaching hospital: the chaos continues. World J Surg 23 (1999) 429-432 discussion 33.
64. Wasey N., Baughan J., and de Gara C.J. Prophylaxis in elective colorectal surgery: the cost of ignoring the evidence. Can J Surg 46 (2003) 279-284
65. Hedrick T.L., and Sawyer R.G. Duration of antimicrobial therapy in intra-abdominal infections. Infect Med 21 (2004) 506-510
66. Smith J.A., Bell G.A., Murphy J., Forward A.D., and Forget J.P. Evaluation of the use of a protocol in the antimicrobial treatment of intra-abdominal sepsis. J Hosp Infect 6 (1985) 60-64
67. Andaker L., Hojer H., Kihlstrom E., and Lindhagen J. Stratified duration of prophylactic antimicrobial treatment in emergency abdominal surgery. Metronidazole-fosfomycin vs. metronidazole-gentamicin in 381 patients. Acta Chir Scand 153 (1987) 185-192
68. Schein M., Assalia A., and Bachus H. Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. Br J Surg 81 (1994) 989-991
69. Taylor E., Dev V., Shah D., Festekjian J., and Gaw F. Complicated appendicitis: is there a minimum intravenous antibiotic requirement?. A prospective randomized trial. Am Surg 66 (2000) 887-890
70. Mazuski J.E., Sawyer R.G., Nathens A.B., et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect (Larchmt) 3 (2002) 161-173
71. Moran G.J., Krishnadasan A., Gorwitz R.J., et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355 7 (2006) 666-674
72. DiNubile M.J., and Lipsky B.A. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 53 2 (2004) ii37-ii50
73. Sachs M.K. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med 150 (1990) 1907-1912
74. Sigurdsson A.F., and Gudmundsson S. The etiology of bacterial cellulitis as determined by fine-needle aspiration. Scand J Infect Dis 21 (1989) 537-542
75. Hepburn M.J., Dooley D.P., Skidmore P.J., Ellis M.W., Starnes W.F., and Hasewinkle W.C. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 164 (2004) 1669-1674
76. Stevens D.L., Bisno A.L., Chambers H.F., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41 (2005) 1373-1406
77. Paydar K.Z., Hansen S.L., Charlebois E.D., Harris H.W., and Young D.M. Inappropriate antibiotic use in soft tissue infections. Arch Surg 141 9 (2006) 850-854 discussion 5-6.
78. Fung H.B., Chang J.Y., and Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 63 (2003) 1459-1480
79. Giordano P., Song J., Pertel P., Herrington J., and Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 26 (2005) 357-365
80. Fabian T.C., File T.M., Embil J.M., et al. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect (Larchmt) 6 (2005) 269-282
81. Gesser R.M., McCarroll K.A., and Woods G.L. Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. J Infect 48 (2004) 32-38
82. Solomkin J., Teppler H., Graham D.R., et al. Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam. J Antimicrob Chemother 53 2 (2004) ii51-ii57
83. Stevens D.L., Smith L.G., Bruss J.B., et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 44 (2000) 3408-3413
84. Jones M.E., Visser M.R., Klootwijk M., Heisig P., Verhoef J., and Schmitz F.J. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 43 (1999) 421-423
85. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., and Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49 (2005) 2260-2266
86. McKinnon P.S., Sorensen S.V., Liu L.Z., and Itani K.M. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 40 (2006) 1017-1023
87. Itani K.M., Weigelt J., Li J.Z., and Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 26 (2005) 442-448
88. Sharpe J.N., Shively E.H., and Polk Jr. H.C. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 189 (2005) 425-428
89. Mascini E.M., Jansze M., Schouls L.M., Verhoef J., and Van Dijk H. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents 18 (2001) 395-398
90. Stevens D.L., Maier K.A., and Mitten J.E. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother 31 (1987) 213-218
91. Stevens D.L., Laine B.M., and Mitten J.E. Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens. Antimicrob Agents Chemother 31 (1987) 312-316
92. Stevens D.L., Gibbons A.E., Bergstrom R., and Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 158 (1988) 23-28
93. Bisno A.L., and Stevens D.L. Streptococcal infections of skin and soft tissues. N Engl J Med 334 (1996) 240-245
94. Vazquez-Aragon P., Lizan-Garcia M., Cascales-Sanchez P., Villar-Canovas M.T., and Garcia-Olmo D. Nosocomial infection and related risk factors in a general surgery service: a prospective study. J Infect 46 (2003) 17-22
95. Jarvis W.R. Infection control and changing health-care delivery systems. Emerg Infect Dis 7 (2001) 170-173
96. Ogawa K., Hirai M., Katsube T., et al. Suppression of cellular immunity by surgical stress. Surgery 127 (2000) 329-336
97. McEachern R., and Campbell Jr. G.D. Hospital-acquired pneumonia: epidemiology, etiology, and treatment. Infect Dis Clin North Am 12 (1998) 761-779
98. Richards M.J., Edwards J.R., Culver D.H., and Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 27 (1999) 887-892
99. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
100. American Thoracic Society, November 1995. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement. Am J Respir Crit Care Med 153 (1996) 1711-1725
101. Grossman R.F., and Fein A. Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia. Executive summary. Chest 117 4 suppl 2 (2000) 177S-181S
102. Shorr A.F., Sherner J.H., Jackson W.L., and Kollef M.H. Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis. Crit Care Med 33 (2005) 46-53
103. Chastre J., Wolff M., Fagon J.Y., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290 (2003) 2588-2598
104. D'Amico R., Pifferi S., Leonetti C., Torri V., Tinazzi A., and Liberati A. Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials. BMJ 316 (1998) 1275-1285
105. Nathens A.B., and Marshall J.C. Selective decontamination of the digestive tract in surgical patients: a systematic review of the evidence. Arch Surg 134 (1999) 170-176
106. Gastinne H., Wolff M., Delatour F., Faurisson F., and Chevret S. A controlled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics. The French Study Group on Selective Decontamination of the Digestive Tract. N Engl J Med 326 (1992) 594-599
107. Sanchez Garcia M., Cambronero Galache J.A., Lopez Diaz J., et al. Effectiveness and cost of selective decontamination of the digestive tract in critically ill intubated patients. A randomized, double-blind, placebo-controlled, multicenter trial. Am J Respir Crit Care Med 158 (1998) 908-916
108. Verwaest C., Verhaegen J., Ferdinande P., et al. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit. Crit Care Med 25 (1997) 63-71
109. de La Cal M.A., Cerda E., Garcia-Hierro P., et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo-controlled, double-blind trial. Ann Surg 241 (2005) 424-430
110. Kollef M.H. Selective digestive decontamination should not be routinely employed. Chest 123 suppl 5 (2003) 464S-468S
111. Cook D.J., Walter S.D., Cook R.J., et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 129 (1998) 433-440
112. Trouillet J.L., Chastre J., Vuagnat A., et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157 (1998) 531-539
113. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
114. Bjork D.T., Pelletier L.L., and Tight R.R. Urinary tract infections with antibiotic resistant organisms in catheterized nursing home patients. Infect Control 5 (1984) 173-176
115. Krieger J.N., Kaiser D.L., and Wenzel R.P. Nosocomial urinary tract infections cause wound infections postoperatively in surgical patients. Surg Gynecol Obstet 156 (1983) 313-318
116. Leone M., Albanese J., Garnier F., et al. Risk factors of nosocomial catheter-associated urinary tract infection in a polyvalent intensive care unit. Intensive Care Med 29 (2003) 1077-1080
117. Hedrick T.L., and Sawyer R.G. Health-care-associated infections and prevention. Surg Clin North Am 85 (2005) 1137-1152
118. Tambyah P.A., Knasinski V., and Maki D.G. The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care. Infect Control Hosp Epidemiol 23 (2002) 27-31
119. Stark R.P., and Maki D.G. Bacteriuria in the catheterized patient. What quantitative level of bacteriuria is relevant?. N Engl J Med 311 (1984) 560-564
120. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., and Hughes J.M. CDC definitions for nosocomial infections, 1988. Am J Infect Control 16 (1988) 128-140
121. Maki D.G., and Tambyah P.A. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis 7 (2001) 342-347
122. Harding G.K., Nicolle L.E., Ronald A.R., et al. How long should catheter-acquired urinary tract infection in women be treated?. A randomized controlled study. Ann Intern Med 114 (1991) 713-719
123. Nicolle L.E., Bradley S., Colgan R., Rice J.C., Schaeffer A., and Hooton T.M. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 40 (2005) 643-654
124. Warren J.W., Abrutyn E., Hebel J.R., Johnson J.R., Schaeffer A.J., and Stamm W.E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 29 (1999) 745-758
125. Jain P., Parada J.P., David A., and Smith L.G. Overuse of the indwelling urinary tract catheter in hospitalized medical patients. Arch Intern Med 155 (1995) 1425-1429
126. Guidelines for preventing catheter associated urinary tract infections-on Internet for consultation. Commun Dis Rep CDR Wkly 10 17 (2000) 149
127. van der Wall E., Verkooyen R.P., Mintjes-de Groot J., et al. Prophylactic ciprofloxacin for catheter-associated urinary-tract infection. Lancet 339 (1992) 946-951
128. Vollaard E.J., Clasener H.A., Zambon J.V., Joosten H.J., and van Griethuysen A.J. Prevention of catheter-associated gram-negative bacilluria with norfloxacin by selective decontamination of the bowel and high urinary concentration. J Antimicrob Chemother 23 (1989) 915-922
129. Verbrugh H.A., Mintjes-de Groot A.J., Andriesse R., Hamersma K., and van Dijk A. Postoperative prophylaxis with norfloxacin in patients requiring bladder catheters. Eur J Clin Microbiol Infect Dis 7 (1988) 490-494
130. Britt M.R., Garibaldi R.A., Miller W.A., Hebertson R.M., and Burke J.P. Antimicrobial prophylaxis for catheter-associated bacteriuria. Antimicrob Agents Chemother 11 (1977) 240-243
131. Platt R., Polk B.F., Murdock B., and Rosner B. Prevention of catheter-associated urinary tract infection: a cost-benefit analysis. Infect Control Hosp Epidemiol 10 (1989) 60-64
132. Mermel L.A., Farr B.M., Sherertz R.J., et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 32 (2001) 1249-1272
133. National Nosocomial Infections Surveillance (NNIS). System Report. Data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32 (2004) 470-485
134. Oncu S., Ozsut H., Yildirim A., et al. Central venous catheter related infections: risk factors and the effect of glycopeptide antibiotics. Ann Clin Microb Antimicrob 2 (2003) 3
135. Pelletier S.J., Crabtree T.D., Gleason T.G., Pruett T.L., and Sawyer R.G. Bacteremia associated with central venous catheter infection is not an independent predictor of outcomes. J Am Coll Surg 190 (2000) 671-680
136. Veenstra D.L., Saint S., and Sullivan S.D. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA 282 (1999) 554-560
137. Maki D.G., Stolz S.M., Wheeler S., and Mermel L.A. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med 127 (1997) 257-266
138. Hanna H.A., Raad I.I., Hackett B., et al. Antibiotic-impregnated catheters associated with significant decrease in nosocomial and multidrug-resistant bacteremias in critically ill patients. Chest 124 (2003) 1030-1038
139. O'Grady N.P., Alexander M., Dellinger E.P., et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 51 RR-10 (2002) 1-29
140. Eggimann P., Harbarth S., Constantin M.N., Touveneau S., Chevrolet J.C., and Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet 355 (2000) 1864-1868
141. Raad I.I., Hohn D.C., Gilbreath B.J., et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 15 4 pt 1 (1994) 231-238
142. Maki D.G., Ringer M., and Alvarado C.J. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 338 (1991) 339-343
143. Sheth N.K., Franson T.R., Rose H.D., Buckmire F.L., Cooper J.A., and Sohnle P.G. Colonization of bacteria on polyvinyl chloride and Teflon intravascular catheters in hospitalized patients. J Clin Microbiol 18 (1983) 1061-1063
144. Pepin J., Valiquette L., Alary M.E., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J 171 (2004) 466-472
145. Privitera G., Scarpellini P., Ortisi G., Nicastro G., Nicolin R., and de Lalla F. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother 35 1 (1991) 208-210
146. Bouza E., Munoz P., and Alonso R. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect 11 suppl 4 (2005) 57-64
147. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 92 (1997) 739-750
148. Fekety R., Silva J., Kauffman C., Buggy B., and Deery H.G. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 86 (1989) 15-19
149. Pepin J., Alary M.E., Valiquette L., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40 (2005) 1591-1597
150. Musher D.M., Aslam S., Logan N., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40 (2005) 1586-1590
151. Wenisch C., Parschalk B., Hasenhundl M., Hirschl A.M., and Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 22 (1996) 813-818
152. Teasley D.G., Gerding D.N., Olson M.M., et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 2 (1983) 1043-1046
153. Bricker E., Garg R., Nelson R., Loza A., Novak T., and Hansen J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 1 (2005) CD004610
154. Young G.P., Ward P.B., Bayley N., et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 89 (1985) 1038-1045
155. Dudley M.N., McLaughlin J.C., Carrington G., Frick J., Nightingale C.H., and Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med 146 (1986) 1101-1104
156. Malnick S.D., and Zimhony O. Treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 36 (2002) 1767-1775
157. Apisarnthanarak A., Razavi B., and Mundy L.M. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 35 (2002) 690-696
158. Friedenberg F., Fernandez A., Kaul V., Niami P., and Levine G.M. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 44 (2001) 1176-1180
159. McFarland L.V., Elmer G.W., and Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97 (2002) 1769-1775
160. Tedesco F.J., Gordon D., and Fortson W.C. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 80 (1985) 867-868
161. Buggy B.P., Fekety R., and Silva Jr. J. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 9 (1987) 155-159
162. Cavagnaro C., Berezin S., and Medow M.S. Corticosteroid treatment of severe, non-responsive Clostridium difficile induced colitis. Arch Dis Child 88 (2003) 342-344
163. Beales I.L. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut 51 (2002) 456
164. Leung D.Y., Kelly C.P., Boguniewicz M., Pothoulakis C., LaMont J.T., and Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 118 4 pt 1 (1991) 633-637
165. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 95 suppl 1 (2000) S11-S13
166. Wullt M., Hagslatt M.L., and Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 35 6-7 (2003) 365-367
167. Plummer S., Weaver M.A., Harris J.C., Dee P., and Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 7 (2004) 59-62
168. Marty F.M., and Rubin R.H. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. Transpl Int 19 (2006) 2-11
169. Tolkoff-Rubin N.E., Cosimi A.B., Russell P.S., and Rubin R.H. A controlled study of trimethoprim-sulfamethoxazole prophylaxis of urinary tract infection in renal transplant recipients. Rev Infect Dis 4 (1982) 614-618
170. Tolkoff-Rubin N.E., and Rubin R.H. Urinary tract infection in the immunocompromised host. Lessons from kidney transplantation and the AIDS epidemic. Infect Dis Clin North Am 11 (1997) 707-717
171. Fox B.C., Sollinger H.W., Belzer F.O., and Maki D.G. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med 89 (1990) 255-274
172. Torre-Cisneros J., De la Mata M., Pozo J.C., et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs.daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clin Infect Dis 29 (1999) 771-774
173. Tolkoff-Rubin N.E., and Rubin R.H. Opportunistic fungal and bacterial infection in the renal transplant recipient. J Am Soc Nephrol 2 suppl 12 (1992) S264-S269
174. Baden L.R., Katz J.T., Franck L., et al. Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole. Transplantation 75 (2003) 339-343
175. Pescovitz M.D. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 82 suppl 2 (2006) S4-S8
176. Pelletier S.J., Crabtree T.D., Gleason T.G., et al. Characteristics of infectious complications associated with mortality after solid organ transplantation. Clin Transplant 14 4 pt 2 (2000) 401-408
177. 65+ in the United States: 2005. 2005. http://www.census.gov/prod/2006pubs/p23-209.pdf.
178. Dominioni L., Imperatori A., Rotolo N., and Rovera F. Risk factors for surgical infections. Surg Infect (Larchmt) 7 suppl 2 (2006) S9-S12